Suzhou Lansen Pharmaceutical

Lansen Pharmaceutical is a specialty pharmaceutical company primarily focused on the development, manufacturing, and commercialization of products in the fields of rheumatology and dermatology in China. The company is well-known for its flagship product, Pafulin (Total Glucosides of Paeony), which is a leading naturally derived disease-modifying anti-rheumatic drug (DMARD). Lansen operates a comprehensive business model that includes research and development, large-scale production facilities in Suzhou and Ningbo, and an extensive distribution network across Chinese hospitals. In addition to its proprietary products, the company manages a portfolio of licensed generic and branded medications targeting autoimmune and inflammatory diseases.